Last updated: December 26, 2023
Sponsor: Chelyabinsk Regional Clinical Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Mitral allograft implantation
Clinical Study ID
NCT06196684
26122023
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failurescheduled for tricuspid valve intervention.
- Intraoperative findings suggested for tricuspid valve replacement rather than repair.
Exclusion
Exclusion Criteria:
- Pregnancy
- Confirmed active drug addiction
- Progressive HIV-infection
- HIV-infected patients with CD4-cells count less than 250
- Patients with secondary tricuspid valve pathology (left-sided valve disease)
- LV Ejection fraction less than 50%
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Mitral allograft implantation
Phase:
Study Start date:
September 29, 2021
Estimated Completion Date:
October 30, 2024
Study Description
Connect with a study center
Department of Cardiac Surgery
Chelyabinsk, 454076
Russian FederationActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.